StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics r&d expenses

Research and development expenses are spending on new products and technology.

Insight Molecular Diagnostics's R&D Expenses for the twelve months ending Jun 30, 2026 was $19.15M, up 69.9% year over year. For fiscal 2025 it was $15.90M, up 61.6% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $15.90M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.90M+61.6%
FY2024Dec 31, 2024$9.84M+5.9%
FY2023Dec 31, 2023$9.29M+27.3%
FY2022Dec 31, 2022$7.30M+45.0%
FY2021Dec 31, 2021$5.04M-48.6%
FY2020Dec 31, 2020$9.80M+44.2%
FY2019Dec 31, 2019$6.79M+4.3%
FY2018Dec 31, 2018$6.51M-9.2%
FY2017Dec 31, 2017$7.17M+26.4%
FY2016Dec 31, 2016$5.68M+25.4%
FY2015Dec 31, 2015$4.53M+14.3%
FY2014Dec 31, 2014$3.96M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.49M+37.2%
Q1 FY2026Mar 31, 2026$4.95M+69.4%
Q4 FY2025Dec 31, 2025$5.83M+158.3%
Q3 FY2025Sep 30, 2025$3.88M+37.7%
Q2 FY2025Jun 30, 2025$3.27M+33.3%
Q1 FY2025Mar 31, 2025$2.92M+26.5%
Q4 FY2024Dec 31, 2024$2.26M-11.4%
Q3 FY2024Sep 30, 2024$2.82M+28.9%
Q2 FY2024Jun 30, 2024$2.45M+0.7%
Q1 FY2024Mar 31, 2024$2.31M+8.7%
Q4 FY2023Dec 31, 2023$2.55M+84.8%
Q3 FY2023Sep 30, 2023$2.19M+48.4%
Q2 FY2023Jun 30, 2023$2.44M-0.4%
Q1 FY2023Mar 31, 2023$2.13M+6.0%
Q4 FY2022Dec 31, 2022$1.38M-70.0%
Q3 FY2022Sep 30, 2022$1.47M-53.2%
Q2 FY2022Jun 30, 2022$2.44M-3.7%
Q1 FY2022Mar 31, 2022$2.01M-40.3%
Q4 FY2021Dec 31, 2021$4.59M+155.1%
Q3 FY2021Sep 30, 2021$3.14M+20.2%
Q2 FY2021Jun 30, 2021$2.54M-21.3%
Q1 FY2021Mar 31, 2021$3.36M+55.7%
Q4 FY2020Dec 31, 2020$1.80M-22.3%
Q3 FY2020Sep 30, 2020$2.62M+60.9%
Q2 FY2020Jun 30, 2020$3.23M+113.9%
Q1 FY2020Mar 31, 2020$2.16M+60.8%
Q4 FY2019Dec 31, 2019$2.32M+92.5%
Q3 FY2019Sep 30, 2019$1.63M+6.4%
Q2 FY2019Jun 30, 2019$1.51M-35.1%
Q1 FY2019Mar 31, 2019$1.34M-8.1%
Q4 FY2018Dec 31, 2018$1.20M-20.1%
Q3 FY2018Sep 30, 2018$1.53M-16.8%
Q2 FY2018Jun 30, 2018$2.32M+16.3%
Q1 FY2018Mar 31, 2018$1.46M-20.3%
Q4 FY2017Dec 31, 2017$1.51M+5.3%
Q3 FY2017Sep 30, 2017$1.84M+34.7%
Q2 FY2017Jun 30, 2017$2.00M–
Q1 FY2017Mar 31, 2017$1.83M–
Q4 FY2016Dec 31, 2016$1.43M–
Q3 FY2016Sep 30, 2016$1.36M–

More Insight Molecular Diagnostics figures

See a number that looks wrong?